HRP20171330T1 - Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola - Google Patents
Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola Download PDFInfo
- Publication number
- HRP20171330T1 HRP20171330T1 HRP20171330TT HRP20171330T HRP20171330T1 HR P20171330 T1 HRP20171330 T1 HR P20171330T1 HR P20171330T T HRP20171330T T HR P20171330TT HR P20171330 T HRP20171330 T HR P20171330T HR P20171330 T1 HRP20171330 T1 HR P20171330T1
- Authority
- HR
- Croatia
- Prior art keywords
- carboxymethyl cellulose
- gossypol
- copolymer
- substitution
- sodium carboxymethyl
- Prior art date
Links
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 title claims 20
- 239000001768 carboxy methyl cellulose Substances 0.000 title claims 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 title claims 11
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 title claims 11
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 title claims 11
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 title claims 10
- 229930000755 gossypol Natural products 0.000 title claims 10
- 229950005277 gossypol Drugs 0.000 title claims 10
- 229920001577 copolymer Polymers 0.000 title claims 7
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 238000006467 substitution reaction Methods 0.000 claims 10
- 208000010877 cognitive disease Diseases 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 208000020706 Autistic disease Diseases 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 229940125681 anticonvulsant agent Drugs 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 239000000935 antidepressant agent Substances 0.000 claims 3
- 229940005513 antidepressants Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- LJKDPUCDUDLUOM-UHFFFAOYSA-N [3,8-diacetyloxy-1-formyl-6-methyl-4-propan-2-yl-7-(1,6,7-triacetyloxy-8-formyl-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalen-2-yl] acetate Chemical compound CC(C)C1=C(OC(C)=O)C(OC(C)=O)=C(C=O)C2=C(OC(C)=O)C(C=3C(OC(C)=O)=C4C(C=O)=C(OC(C)=O)C(OC(C)=O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 LJKDPUCDUDLUOM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000012670 alkaline solution Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
- C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/02—Oxycellulose; Hydrocellulose; Cellulosehydrate, e.g. microcrystalline cellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Claims (10)
1. Postupak proizvodnje kopolimera natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1) :
[image]
gdje je
a:b:c = 1 : (3-6) : (5-7),
n = 40-50;
s molekularnom težinom od 120,000-130,000, postupak sadrži reakciju vodene otopine natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 s vodenom otopinom perjodatne kiseline ili natrijevim perjodatom, nakon čega slijedi izolacija dialdehida karboksimetil celuloze, obrada nastalog produkta s gosipolom ili gosipol-octenom kiselinom i zatim s vodenom alkalnom otopinom, te izoliranje željenog proizvoda taloženjem s organskim otapalom, naznačen time da vodena otopina natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 reagira s vodenom otopinom perjodatne kiseline ili natrijevim perjodatom kada pri prolasku ugljikovog dioksida kroz reakcijsku otopinu do dostizanja pH od 3.0 do 4.5.
2. Kopolimer natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1) :
[image]
gdje je
a:b:c = 1 : (3-6) : (5-7),
n = 40-50;
s molekularnom težinom od 120,000-130,000,
naznačen time da je za upotrebu u kompleksnoj terapiji pacijenata s autističnim poremećajima i kognitivni oštećenjima.
3. Kopolimer za upotrebu prema zahtjevu 2, naznačen time da se kopolimer natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1), proizvodi postupkom prema zahtjevu 1.
4. Kopolimer za upotrebu prema zahtjevu 2 ili 3, naznačen time da se kopolimer natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1) koristi u kombinaciji s lijekom za liječenje kognitivnih poremećaja, koji se biraju od jednog ili više neuroleptika, antidepresiva, antikonvulziva ili njihove kombinacije.
5. Farmaceutski pripravak za upotrebu u kompleksnoj terapiji pacijenata s autističnim poremećajima i kognitivnim oštećenjima, koji sadrži, kao aktivno sredstvo, terapeutski učinkovitu količinu kopolimera natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1)
[image]
gdje je
a:b:c = 1 : (3-6) : (5-7),
n = 40-50;
s molekularnom težinom od 120,000-130,000, i farmaceutski prihvatljive aditive.
6. Farmaceutski pripravak za upotrebu prema zahtjevu 5,
naznačen time da sadrži slijedeće komponente, izraženo u masenim %:
aktivno sredstvo s formulom (1) - 10.0-16.0,
škrob - 10.0-20.0,
kalcijev ili magnezijev stearat - 0.6-0.8
Ludipress - do 100.
7. Farmaceutski pripravak za upotrebu prema zahtjevu 5 ili 6, naznačen time da je za upotrebu u kombinaciji s lijekom za liječenje kognitivnih poremećaja, koji se bira od jednog ili više neuroleptika, antidepresiva, antikonvulziva ili njihove kombinacije.
8. Kombinirani farmaceutski proizvod za upotrebu u kompleksnoj terapiji pacijenata s autističnim poremećajima i kognitivnim oštećenjima, naznačen time da sadrži terapeutski učinkovitu količinu kopolimera natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1)
[image]
gdje je
a:b:c = 1 : (3-6) : (5-7),
n = 40-50;
s molekularnom težinom od 120,000-130,000, ili farmaceutskog pripravka prema zahtjevu 5 ili 6; i terapeutski učinkovitu količinu lijeka za liječenje kognitivnih poremećaja, koji se bira od jednog ili više neuroleptika, antidepresiva, antikonvulziva ili njihove kombinacije.
9. Upotreba kopolimera natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipola, s formulom (1)
[image]
gdje je
a:b:c = 1 : (3-6) : (5-7),
n = 40-50;
s molekularnom težinom od 120,000-130,000, za proizvodnju farmaceutskog pripravka prema zahtjevu 5 ili 6, naznačena time da je za upotrebu u kompleksnoj terapiji pacijenata s autističnim poremećajima i kognitivnim oštećenjima.
10. Upotreba prema zahtjevu 9 naznačena time da se kopolimer natrijeve karboksimetil celuloze sa stupnjem supstitucije od 0.35 do 0.80 i gosipol, s formulom (1) proizvodi postupkom prema zahtjevu 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010141697/05A RU2453559C1 (ru) | 2010-10-11 | 2010-10-11 | Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями |
| EP11832823.6A EP2628754B8 (en) | 2010-10-11 | 2011-10-06 | Method for producing and using a copolymer of sodium carboxymethyl cellulose and gossypol |
| PCT/RU2011/000785 WO2012050483A1 (ru) | 2010-10-11 | 2011-10-06 | Способ получения и применение сополимера натрийкарбоксиметилцеллюлозы и госсипола |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171330T1 true HRP20171330T1 (hr) | 2017-10-20 |
Family
ID=45938511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171330TT HRP20171330T1 (hr) | 2010-10-11 | 2017-09-05 | Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9078916B2 (hr) |
| EP (1) | EP2628754B8 (hr) |
| JP (1) | JP5690944B2 (hr) |
| CN (1) | CN103189393B (hr) |
| AU (1) | AU2011314406B2 (hr) |
| BR (1) | BR112013008888B1 (hr) |
| CA (2) | CA2896450A1 (hr) |
| CL (2) | CL2013000962A1 (hr) |
| CO (1) | CO6731081A2 (hr) |
| CY (1) | CY1119413T1 (hr) |
| DK (1) | DK2628754T3 (hr) |
| EA (2) | EA024810B1 (hr) |
| EC (1) | ECSP13012613A (hr) |
| ES (1) | ES2643167T3 (hr) |
| GE (1) | GEP201706607B (hr) |
| HR (1) | HRP20171330T1 (hr) |
| HU (1) | HUE034920T2 (hr) |
| LT (1) | LT2628754T (hr) |
| PE (1) | PE20140200A1 (hr) |
| PL (1) | PL2628754T3 (hr) |
| PT (1) | PT2628754T (hr) |
| RS (1) | RS56257B1 (hr) |
| RU (1) | RU2453559C1 (hr) |
| SI (1) | SI2628754T1 (hr) |
| UA (2) | UA108126C2 (hr) |
| WO (1) | WO2012050483A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2499002C1 (ru) * | 2012-06-14 | 2013-11-20 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Конъюгаты госсипола и натрийкарбоксиметилцеллюлозы, способы их получения и противовирусные средства на их основе |
| RU2577539C2 (ru) * | 2014-06-17 | 2016-03-20 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Полимерные производные госсипола, способ их получения и фармацевтическая композиция на их основе |
| RU2754067C2 (ru) * | 2018-05-18 | 2021-08-25 | Общество с ограниченной ответственностью "НИАРМЕДИК ФАРМА" | Противомикробная композиция на основе полифенолов и полисахаридов, способ ее получения и применение |
| RU2746504C1 (ru) * | 2020-02-27 | 2021-04-14 | Ниармедик Интернэшнл Лимитед | Противомикробные средства на основе бета-глюканов, способы их получения и применения |
| JP7207364B2 (ja) | 2020-05-19 | 2023-01-18 | Ｊｆｅスチール株式会社 | ロッドミルのロッド交換装置及び方法 |
| CN114622407B (zh) * | 2022-04-01 | 2023-09-19 | 浙江隆腾医用新材料有限公司 | 一种羧甲基纤维素钠纤维的洗脱方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2002755C1 (ru) * | 1991-02-04 | 1993-11-15 | Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН | Производное целлюлозы и госсипола, обладающее интерферониндуцирующим и противовирусным действием |
| RU2222548C2 (ru) * | 2000-07-21 | 2004-01-27 | Зао "Ниармедик Плюс" | Применение производного целлюлозы и госсипола в качестве радиопротекторного, противоинфекционного и потенциирующего средства, усовершенствованный способ его получения и фармацевтическая композиция на его основе |
| JP4445853B2 (ja) * | 2002-06-10 | 2010-04-07 | ワイス エルエルシー | 新規ｏ−デスメチルベンラファクシンギ酸塩 |
| DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| RU2238122C1 (ru) * | 2003-01-20 | 2004-10-20 | Ооо "Ниармедик Плюс" | Противоинфекционный фармацевтический препарат |
| RU2270708C1 (ru) * | 2004-05-26 | 2006-02-27 | Ооо "Ниармедик Плюс" | Натриевая соль сополимера карбоксиметилцеллюлозы и госсипола, фармацевтическая композиция и способ профилактики или лечения вирусных заболеваний |
| US20060144723A1 (en) * | 2004-11-02 | 2006-07-06 | Mary Fuller | Device for securing valuables |
| US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| US20090285865A1 (en) * | 2008-05-14 | 2009-11-19 | Shalaby Shalaby W | Palatable, solid oral formulations for male chemical sterilization |
-
2010
- 2010-10-11 RU RU2010141697/05A patent/RU2453559C1/ru active
-
2011
- 2011-06-10 UA UAA201305876A patent/UA108126C2/ru unknown
- 2011-10-06 AU AU2011314406A patent/AU2011314406B2/en not_active Ceased
- 2011-10-06 EA EA201390530A patent/EA024810B1/ru active IP Right Revival
- 2011-10-06 CA CA2896450A patent/CA2896450A1/en not_active Abandoned
- 2011-10-06 ES ES11832823.6T patent/ES2643167T3/es active Active
- 2011-10-06 GE GEAP201113083A patent/GEP201706607B/en unknown
- 2011-10-06 RS RS20170877A patent/RS56257B1/sr unknown
- 2011-10-06 SI SI201131286T patent/SI2628754T1/en unknown
- 2011-10-06 PL PL11832823T patent/PL2628754T3/pl unknown
- 2011-10-06 WO PCT/RU2011/000785 patent/WO2012050483A1/ru active Application Filing
- 2011-10-06 JP JP2013533814A patent/JP5690944B2/ja not_active Expired - Fee Related
- 2011-10-06 US US13/877,416 patent/US9078916B2/en not_active Expired - Fee Related
- 2011-10-06 LT LTEP11832823.6T patent/LT2628754T/lt unknown
- 2011-10-06 BR BR112013008888-5A patent/BR112013008888B1/pt not_active IP Right Cessation
- 2011-10-06 HU HUE11832823A patent/HUE034920T2/en unknown
- 2011-10-06 UA UAA201411350A patent/UA108975C2/ru unknown
- 2011-10-06 EA EA201690544A patent/EA031316B1/ru active IP Right Revival
- 2011-10-06 PT PT118328236T patent/PT2628754T/pt unknown
- 2011-10-06 DK DK11832823.6T patent/DK2628754T3/da active
- 2011-10-06 PE PE2013000829A patent/PE20140200A1/es active IP Right Grant
- 2011-10-06 CA CA2811583A patent/CA2811583C/en not_active Expired - Fee Related
- 2011-10-06 EP EP11832823.6A patent/EP2628754B8/en active Active
- 2011-10-06 CN CN201180048898.4A patent/CN103189393B/zh not_active Expired - Fee Related
-
2013
- 2013-04-10 CL CL2013000962A patent/CL2013000962A1/es unknown
- 2013-05-09 EC ECSP13012613 patent/ECSP13012613A/es unknown
- 2013-05-10 CO CO13117014A patent/CO6731081A2/es unknown
-
2015
- 2015-05-05 CL CL2015001180A patent/CL2015001180A1/es unknown
-
2017
- 2017-09-05 HR HRP20171330TT patent/HRP20171330T1/hr unknown
- 2017-09-14 CY CY20171100974T patent/CY1119413T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171330T1 (hr) | Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola | |
| JP2014198723A5 (hr) | ||
| AU2018236805B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
| RU2014133501A (ru) | Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением | |
| US20080261984A1 (en) | Use of S,S-Reboxetine in the Treatment of Pain | |
| JP2013520405A5 (hr) | ||
| WO2011017201A3 (en) | Dp2 antagonist and uses thereof | |
| EA201270505A1 (ru) | Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение | |
| MX2011011428A (es) | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. | |
| WO2010133686A8 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| EA201270069A1 (ru) | Быстрорастворимая оральная пленочная лекарственная форма, содержащая стевиозиды в качестве агента, маскирующего неприятный вкус | |
| MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| JP2009545637A5 (hr) | ||
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| MX362830B (es) | Agente terapeutico o profilactico para enfermedades del tracto biliar. | |
| EA201490166A1 (ru) | Фторированные арилалкиламинокарбоксамидные производные | |
| ATE526015T1 (de) | Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien | |
| JP2013510187A (ja) | 誘発されたジスキネジアを治療又は予防するためのキセノンベースの吸入可能薬物 | |
| NZ598702A (en) | A micro-rna family that modulates fibrosis and uses thereof | |
| CO6410283A2 (es) | Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas | |
| WO2022115944A8 (en) | Carboxylated psilocybin derivatives and methods of using | |
| JP2015528515A5 (hr) | ||
| CA3154083A1 (en) | Methods of promoting scfa production by gut microbiota | |
| RU2018125252A (ru) | Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции |